CUE
Cue Biopharma, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
24.40
▼ 0.21 (0.85%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
25.98
Prev close
24.61
Day high
26.00
Day low
23.24
Volume
177.06K
Market cap
—
P/E (TTM)
—
52W range
4.98 – 45.50
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-29.88%
-28.5%
1M
-27.53%
-31.3%
3M
+19.30%
+16.2%
6M
+180.47%
+169.4%
YTD
+162.08%
+149.8%
1Y
-1.07%
-21.1%
3Y
-73.44%
-147.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $27.47M | $9.29M | $5.49M | $1.25M | — | +195.7% |
| Operating revenue | $27.47M | $9.29M | $5.49M | $1.25M | — | +195.7% |
| Research & development | $37.74M | $36.30M | $40.80M | $38.58M | — | +4.0% |
| Selling, general & admin | $16.24M | $14.59M | $16.68M | $16.17M | — | +11.4% |
| Total operating expense | $53.99M | $50.88M | $57.48M | $54.75M | — | +6.1% |
| Operating income | -$26.52M | -$41.59M | -$51.99M | -$53.50M | — | +36.2% |
| Net interest income | $450.00K | $826.00K | $1.42M | $215.00K | — | -45.5% |
| Pre-tax income | -$26.10M | -$40.67M | -$50.73M | -$53.01M | — | +35.8% |
| Tax provision | $500.00K | $0 | — | $0 | $495.00K | — |
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Net income to common | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Basic EPS | -8.40 | -21.60 | -33.30 | -44.70 | — | +61.1% |
| Diluted EPS | -8.40 | -21.60 | -33.30 | -44.70 | — | +61.1% |
| EBIT | -$25.75M | -$39.88M | -$49.49M | -$52.30M | — | +35.4% |
| EBITDA | -$22.27M | -$37.53M | -$46.05M | -$50.49M | — | +40.7% |
| Basic shares | 3.16M | 1.88M | 1.53M | 1.19M | — | +68.2% |
| Diluted shares | 3.16M | 1.88M | 1.53M | 1.19M | — | +68.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $27.14M | $22.46M | $48.51M | $51.61M | +20.8% |
| Cash & short-term investments | $27.14M | $22.46M | $48.51M | $76.29M | +20.8% |
| Accounts receivable | $5.55M | $945.00K | $1.70M | $57.00K | +486.9% |
| Total current assets | $36.98M | $25.14M | $51.45M | $77.19M | +47.1% |
| Property, plant & equipment | $4.32M | $4.84M | $7.12M | $10.70M | -10.9% |
| Total assets | $42.21M | $32.19M | $61.53M | $91.28M | +31.1% |
| Total current liabilities | $13.49M | $13.69M | $17.08M | $11.55M | -1.4% |
| Current debt | — | $4.33M | $3.96M | $1.96M | — |
| Long-term debt | — | — | $4.20M | $8.04M | — |
| Total debt | $4.20M | $8.88M | $14.70M | $19.32M | -52.7% |
| Total liabilities | $15.78M | $14.69M | $24.45M | $25.60M | +7.4% |
| Retained earnings | -$368.47M | -$341.86M | -$301.19M | -$250.46M | -7.8% |
| Shareholder equity | $26.43M | $17.50M | $37.09M | $65.68M | +51.0% |
| Working capital | $23.49M | $11.45M | $34.37M | $65.64M | +105.2% |
| Net tangible assets | $26.43M | $17.50M | $37.09M | $65.68M | +51.0% |
| Shares issued | 3.22M | 2.06M | 1.57M | 1.43M | +56.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Depreciation & amortisation | $3.48M | $2.35M | $3.44M | $1.81M | — | +48.1% |
| Stock-based compensation | $4.74M | $6.85M | $8.18M | $9.50M | — | -30.7% |
| Change in working capital | -$3.29M | -$4.92M | -$934.00K | $356.00K | — | +33.1% |
| Operating cash flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | — | +40.3% |
| Capital expenditure | -$177.00K | -$66.00K | — | -$171.00K | -$913.04K | -168.2% |
| Investing cash flow | $75.00K | $32.00K | $25.00M | -$24.61M | — | +134.4% |
| Financing cash flow | $26.29M | $10.24M | $11.86M | $53.66M | — | +156.7% |
| Free cash flow | -$21.86M | -$36.40M | -$39.96M | -$41.98M | — | +39.9% |
| End cash position | $27.29M | $22.61M | $48.66M | $51.76M | — | +20.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $5.69M | $21.94M | $2.15M | $2.95M | $421.00K | -74.1% |
| Operating revenue | $5.69M | $21.94M | $2.15M | $2.95M | $421.00K | -74.1% |
| Research & development | $6.90M | $16.53M | $4.75M | $7.91M | $8.55M | -58.3% |
| Selling, general & admin | $4.15M | $3.45M | $4.94M | $3.67M | $4.17M | +20.3% |
| Total operating expense | $11.05M | $19.98M | $9.69M | $11.59M | $12.72M | -44.7% |
| Operating income | -$5.36M | $1.96M | -$7.54M | -$8.63M | -$12.30M | -373.9% |
| Net interest income | $175.00K | $107.00K | $147.00K | $153.00K | $42.00K | +63.6% |
| Pre-tax income | -$5.18M | $2.08M | -$7.45M | -$8.48M | -$12.26M | -348.3% |
| Net income | -$5.18M | $1.58M | -$7.45M | -$8.48M | -$12.26M | -426.7% |
| Net income to common | -$5.18M | $1.58M | -$7.45M | -$8.48M | -$12.26M | -426.7% |
| Basic EPS | -1.08 | 0.30 | -2.10 | -2.70 | -4.95 | -460.0% |
| Diluted EPS | -1.08 | 0.30 | -2.10 | -2.70 | -4.95 | -460.0% |
| EBIT | -$5.17M | $2.14M | -$7.37M | -$8.44M | -$12.13M | -342.2% |
| EBITDA | -$4.25M | $3.34M | -$6.78M | -$7.64M | -$11.25M | -227.0% |
| Basic shares | 4.81M | 3.60M | 3.36M | 3.18M | 2.48M | +33.6% |
| Diluted shares | 4.81M | 3.68M | 3.36M | 3.18M | 2.48M | +30.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.38M | $27.14M | $11.70M | $27.49M | $13.14M | — | -39.6% |
| Cash & short-term investments | $16.38M | $27.14M | $18.67M | $27.49M | $13.14M | — | -39.6% |
| Accounts receivable | $5.35M | $5.55M | $387.00K | $532.00K | $0 | — | -3.5% |
| Total current assets | $26.39M | $36.98M | $25.82M | $30.84M | $15.93M | — | -28.6% |
| Property, plant & equipment | $3.61M | $4.32M | $4.91M | $5.57M | $4.11M | — | -16.4% |
| Total assets | $30.88M | $42.21M | $31.64M | $40.71M | $22.25M | — | -26.9% |
| Total current liabilities | $7.39M | $13.49M | $15.52M | $19.25M | $15.50M | — | -45.2% |
| Current debt | — | — | $1.46M | $2.42M | $3.37M | $4.33M | — |
| Total debt | $3.44M | $4.20M | $6.17M | $7.63M | $7.13M | — | -18.0% |
| Total liabilities | $9.27M | $15.78M | $18.40M | $22.55M | $15.67M | — | -41.3% |
| Retained earnings | -$373.64M | -$368.47M | -$370.05M | -$362.60M | -$354.12M | — | -1.4% |
| Shareholder equity | $21.61M | $26.43M | $13.25M | $18.16M | $6.58M | — | -18.3% |
| Working capital | $19.00M | $23.49M | $10.29M | $11.59M | $433.00K | — | -19.1% |
| Net tangible assets | $21.61M | $26.43M | $13.25M | $18.16M | $6.58M | — | -18.3% |
| Shares issued | 3.26M | 3.22M | 2.59M | 2.55M | 2.06M | — | +1.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$5.18M | $1.58M | -$7.45M | -$8.48M | -$12.26M | — | -426.7% |
| Depreciation & amortisation | $929.00K | $1.21M | $596.00K | $796.00K | $882.00K | — | -23.0% |
| Stock-based compensation | $48.00K | $610.00K | $1.53M | $1.26M | $1.34M | — | -92.1% |
| Change in working capital | -$6.73M | -$4.47M | -$3.62M | $2.97M | $1.82M | — | -50.6% |
| Operating cash flow | -$10.94M | -$1.08M | -$9.02M | -$3.42M | -$8.17M | — | -916.9% |
| Capital expenditure | -$121.00K | — | — | -$27.00K | -$150.00K | -$2.00K | — |
| Investing cash flow | -$121.00K | $7.02M | -$6.77M | -$27.00K | -$150.00K | — | -101.7% |
| Financing cash flow | $306.00K | $9.49M | $1.00K | $17.80M | -$1.00M | — | -96.8% |
| Free cash flow | -$11.06M | -$1.08M | -$9.02M | -$3.44M | -$8.32M | — | -928.2% |
| End cash position | $16.53M | $27.29M | $11.85M | $27.64M | $13.29M | — | -39.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
27.83
-12.31% from price
SMA 20
28.03
-14.44% from price
SMA 50
29.16
-17.78% from price
SMA 100
25.14
-2.94% from price
SMA 200
18.47
+29.81% from price
EMA 12
27.23
-10.41% from price
EMA 26
28.25
-13.61% from price
EMA 50
27.91
-12.59% from price
RSI (14)
40.3
Neutral
MACD (12,26,9)
-1.01
Hist -0.50
ATR (14)
3.36
14.00% of price
Realised vol 30D
118.9%
Annualised
Bollinger upper
33.19
20, 2σ
Bollinger lower
22.86
20, 2σ
50 / 200 cross
Golden
29.16 vs 18.47
Trend bias
Above 200
+29.81%
Risk profile
Beta vs SPY
3.01
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
118.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-80.9%
Peak to trough
Max drawdown 5Y
-99.0%
Peak to trough
ATR 14
3.36
14.00% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 8d ago
Cue Biopharma Names James Ahlers CFO Following FDA Filing for CUE-221 in Food Allergy
MT Newswires · 19d ago
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
GlobeNewswire · 20d ago
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Simply Wall St. · 30d ago
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
GlobeNewswire · 40d ago
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
GlobeNewswire · 41d ago
Top Midday Gainers
MT Newswires · 43d ago
Cue Biopharma Announces $50 Million Private Placement
MT Newswires · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.